Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.
Bersanelli M, Buti S, Banna GL, De Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, De Tursi M, Di Marino P, Rossetti S, Rossi E, Tomao S, De Luca E, Sorarù M, Mucciarini C, Atzori F, La Torre L, Vitale MG, Martelli V, Sepe P, Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Di Maio M, Verzoni E, Procopio G, Giannarelli D. Bersanelli M, et al. Among authors: mazzoni f. Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180. Immunotherapy. 2020. PMID: 32089035
Medical treatment of brain metastases from solid tumours.
Cappuzzo F, Mazzoni F, Maestri A, Di Stefano A, Calandri C, Crino L. Cappuzzo F, et al. Among authors: mazzoni f. Forum (Genova). 2000 Apr-Jun;10(2):137-48. Forum (Genova). 2000. PMID: 10875975 Review.
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L. Chiari R, et al. Among authors: mazzoni f. Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. Clin Lung Cancer. 2014. PMID: 25087901 No abstract available.
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, Mazzoni F, Maddau C, Naldi N, Sammarelli G, Frati C, Pinto C, Ardizzoni A. Bozzetti C, et al. Among authors: mazzoni f. Diagn Cytopathol. 2015 Nov;43(11):941-6. doi: 10.1002/dc.23318. Epub 2015 Jul 7. Diagn Cytopathol. 2015. PMID: 26152804
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.
Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S. Bersanelli M, et al. Among authors: mazzoni f. Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080. Immunotherapy. 2018. PMID: 30326787 Free article.
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC). Tibaldi C, et al. Among authors: mazzoni f. Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8. Br J Cancer. 2018. PMID: 30405211 Free PMC article.
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, de Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F. Landi L, et al. Among authors: mazzoni f. Clin Cancer Res. 2019 Dec 15;25(24):7312-7319. doi: 10.1158/1078-0432.CCR-19-0994. Epub 2019 Aug 15. Clin Cancer Res. 2019. PMID: 31416808 Clinical Trial.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. Facchinetti F, et al. Among authors: mazzoni f. Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25. Eur J Cancer. 2020. PMID: 32220780
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Cortellini A, et al. Among authors: mazzoni f. Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30. Cancer Immunol Immunother. 2020. PMID: 32474768 Free PMC article.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Cortellini A, et al. Among authors: mazzoni f. Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21. Clin Lung Cancer. 2020. PMID: 32680806
120 results